Human iPSC-Derived Cardiomyocytes for High Throughput In Vitro Cardiac Pharmacology and Cardiotoxicity Studies

The poster Human iPSC-Derived Cardiomyocytes for High Throughput In Vitro Cardiac Pharmacology and Cardiotoxicity Studies presents Axol Bioscience’s axoCells™ ventricular cardiomyocytes as a scalable and physiologically relevant model for cardiac drug screening.

Key highlights include:

• Electrophysiological Profiling: Naᵥ and Caᵥ currents recorded using Sophion’s QPatch and Qube 384 platforms. Naᵥ1.5 channels confirmed via TTX sensitivity; Caᵥ1.2 channels modulated by nifedipine and Bay K8644.
• Action Potential Measurements: Paced APs analyzed for amplitude, duration (APD90), and pharmacological modulation.
• High Success Rates: Up to 40% whole-cell success on QPatch and 80% on Qube 384 using seal-enhancing solutions.
• Drug Response Assays:
  • Tetrodotoxin (TTX): Dose-dependent inhibition of Naᵥ currents.
  • Tetracaine: IC₅₀ values aligned with published Naᵥ1.5 data.
  • Bay K8644 & Nifedipine: Modulate Caᵥ currents and APD90.
• Scalability & Reproducibility: Enables early-stage cardiac safety screening with human-relevant data, reducing reliance on animal models.

This platform supports efficient, reproducible, and physiologically relevant cardiac pharmacology workflows for preclinical drug development.

Featured Axol Products:

• axoCells™ Ventricular Cardiomyocytes – ax2508